CELG Celgene Corporation

   By Colin Kellaher 
 

Bristol-Myers Squibb Co. (BMY) on Thursday said it expects to report 2019 earnings, excluding any impact from its planned acquisition of Celgene Corp. (CELG), that would exceed Wall Street's expectations.

The New York drug maker said it expects adjusted earnings of $4.10 to $4.20 a share this year, along with reported earnings of $3.75 to $3.85 a share.

Analysts polled by FactSet were expecting an adjusted profit of $4.09 a share and reported earnings of $3.50 a share.

Bristol-Myers earlier Thursday said it agreed to buy Celgene in a cash and stock deal valued at about $74 billion, with an expected closing in the third quarter of 2019.

Bristol-Myers said it will provide full guidance for 2019 on Jan. 24, when it reports its fourth-quarter results.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 03, 2019 08:01 ET (13:01 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.